Alexion’s Soliris REMS Working Well But Might Benefit From Small Changes

FDA advisory committee will weigh potential tweaks to orphan drug’s risk management plan, which is meeting informational goals regarding meningococcal infections but could be burdening prescribers with repeated assessments.